Plain-English translation of NCT06390306 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This trial is testing a new treatment approach for a serious form of chronic myeloid leukemia (CML) called myeloid blast phase, which progresses quickly and is hard to treat. The study combines three medications: a newer type of drug called a third-generation tyrosine kinase inhibitor, , and (a drug that helps kill cancer cells). Researchers want to see if this three-drug combination is effective and safe for patients with this advanced form of leukemia.
The myeloid blast phase of CML has very poor outcomes, and there is no standard, agreed-upon treatment approach yet. This medication combination has shown promise in early studies and is already used successfully for a related blood cancer, so researchers want to test whether it works well in this harder-to-treat form of CML.
You likely qualify if…
You likely don't qualify if…
You would take the three-drug combination as directed by the research team, likely on an outpatient basis. You would have regular clinic visits for blood tests, imaging, and check-ups to monitor how well the treatment is working and whether you experience any side effects. The trial will also collect blood or tissue samples to help researchers understand which patients benefit most from this treatment approach.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China